Breaking News, Collaborations & Alliances

Cassava Sciences Enters Drug Supply Agreement with Evonik

Evonik will supply Cassava Sciences with large-scale, clinical-grade quantities of simufilam.

Author Image

By: Charlie Sternberg

Associate Editor

Cassava Sciences Inc., a clinical-stage biotechnology company developing product candidates for Alzheimer’s disease, has entered into a drug supply agreement with Evonik Industries AG for simufilam. Under the agreement, Evonik will supply Cassava Sciences with large-scale, clinical-grade quantities of simufilam, a drug candidate for the treatment of Alzheimer’s disease.   “I am pleased with our success to date in being an effective collaborator with Evonik, a company with a long, successful and ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters